Skip to content

Study on the Effectiveness and Safety of Fermented Lotus Leaf Compound Protein Powder in Intervening Adult Overweight/Mildly Obese Individuals

Study on the Effectiveness and Safety of Fermented Lotus Leaf Compound Protein Powder in Intervening Adult Overweight/Mildly Obese Individuals

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121809
Enrollment
Unknown
Registered
2026-04-03
Start date
2025-10-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight/Mildly Obese

Interventions

Overweight Intervention Group:This experiment was a self before and after control.Dietary guidance was given, daily dietary energy intake was 800~1500Kcal, to ensure the daily water intake of 2000ml,
Mild obesity intervention group:This experiment was a self before and after control.Dietary guidance was given, daily dietary energy intake was 800~1500Kcal, to ensure the daily water intake of 2000ml

Sponsors

Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. According to the diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Obesity (2024), body mass index (BMI) = body weight (kg)/height^2 (m^2), 24 kg/m^2 25% in men and > 30% in women. 2. Age 18-60 years old (including the threshold), male or female; 3. Did not participate in clinical research, or after participating in clinical research has stopped the drug elution for more than 6 months; 4. Be able to understand the procedures and methods of the study, be willing and able to maintain a stable diet and exercise lifestyle during the study period, and voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Use of psychoactive substances, drug abuse and dependence; 2. People who have had allergies to the components of the intervention used in this study; 3. Women who are pregnant or breastfeeding, or those who need to prepare for pregnancy; 4. Secondary obesity; 5. Patients with diabetes (except pre-diabetes), heart disease, liver and kidney insufficiency, mental disease, systemic infectious disease, gastrointestinal disease; 6. There is a deformity or deformity of the limb that affects the measurement of height and weight; 7. Those with a history of alcohol abuse within 6 months prior to screening; 8. Those who have taken any weight loss measures or medication in the 6 months prior to screening; 9. Factors judged by other researchers to be unsuitable for participation in the experiment exist.

Design outcomes

Primary

MeasureTime frame
Weight;Height;Waist circumference;Hip circumference;Skinfold thickness;Total body fat;Body fat rate;Total cholesterol, TC;Triglycerides, TG;Low-density lipoprotein cholesterol, LDL-C;High-density lipoprotein cholesterol, HDL-C;Body mass index, BMI;superconducting gravity gradiometer;

Secondary

MeasureTime frame
Blood pressure, BP;Aspartate aminotransferase, AST ;Alanine aminotransferase, ALT;Blood urea nitrogen, BUN;Creatinine, CR;Uric acid, UA;Serum interleukin-6;Adiponectin;Leptin;Blood glucose, BG;C-reactive protein,CRP;Satiety index;

Countries

China

Contacts

Public ContactHui Liang

College of Public Health, Medical College, Qingdao University

qdlianghui@126.com+86 186 1532 9686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026